Core Viewpoint - The ongoing dispute over the exclusive agency rights for AestheFill products between Aimeike and Datou Medical has significant implications for Aimeike's future performance and market position [2][8]. Group 1: Arbitration and Legal Proceedings - Aimeike's subsidiary REGEN has sent a termination notice to Datou Medical, ending their exclusive distribution agreement for AestheFill products in mainland China [2]. - Datou Medical has filed for arbitration with the Shenzhen International Arbitration Court, seeking to confirm the validity of the exclusive agency agreement and demanding REGEN to continue fulfilling the contract [2][3]. - Datou Medical is claiming damages amounting to 1.6 billion yuan if their arbitration requests are not upheld [2]. Group 2: Financial Performance - Aimeike's revenue and net profit growth have significantly slowed, with 2024 showing a revenue increase of only 5.45% and a net profit increase of 5.33%, compared to much higher growth rates in 2023 [5]. - In the first half of 2025, Aimeike reported a revenue of 1.299 billion yuan, a decline of 21.59%, and a net profit of 789 million yuan, down 29.57% year-on-year [5]. - The revenue from solution and gel injection products, which are key income sources, has also seen a decline, with respective decreases of 23.79% and 23.99% in the first half of 2025 [5][6]. Group 3: Market Position and Strategy - Aimeike is focusing on diversifying its product offerings to mitigate competitive pressures in the increasingly crowded market for aesthetic products [6][7]. - The company is expanding its product pipeline in areas such as metabolic diseases and major surgeries, while also accelerating the development of products like botulinum toxin and collagen [6]. - Aimeike emphasizes that its product safety and efficacy have been validated globally, and it aims to provide a broader range of solutions to meet diverse consumer needs [7].